TY - JOUR
T1 - Comparative study between 3D-QSAR and Docking-Based Pharmacophore models for potent Plasomodium falciparum dihydroorotate dehydrogenase inhibitors
AU - Tseng, Tien-Sheng
AU - Lee, Yu-Ching
AU - Hsiao, Nai-Wan
AU - Liu, Yun-Ru
AU - Tsai, Keng-Chang
N1 - Export Date: 28 March 2016
CODEN: BMCLE
通訊地址: Tsai, K.-C.; National Research Institute of Chinese Medicine, No. 155-1, Sec. 2, Linong St., Taiwan; 電子郵件: [email protected]
化學物質/CAS: dihydroorotate dehydrogenase, 9029-03-2
出資詳情: 103-2320-B-077-001-MY3, MOST, Ministry of Science and Technology
出資詳情: MOHW104-TDU-B-212-124-001, MOHW, Ministry of Science and Technology
參考文獻: Fidock, D.A., Rosenthal, P.J., Croft, S.L., Brun, R., Nwaka, S., (2004) Nat. Rev. Drug Disc., 3, p. 509; Cui, L., Su, X.Z., (2009) Expert Rev. Anti-Infect. Ther., 7, p. 999; Pohlit, A.M., Lima, R.B., Frausin, G., Silva, L.F., Lopes, S.C., Moraes, C.B., Cravo, P., Costa, F.T., (2013) Molecules, 18, p. 9219; Schwartz, L., Brown, G.V., Genton, B., Moorthy, V.S., (2012) Malar. J., 11, p. 11; Challenges in Malaria Research: Core Science and Innovation (2014) Malar. J., 13, pp. O2-P107; Downie, M.J., Kirk, K., Mamoun, C.B., (2008) Eukaryot. Cell, 7, p. 1231; Baldwin, J., Farajallah, A.M., Malmquist, N.A., Rathod, P.K., Phillips, M.A., (2002) J. Biol. Chem., 277, p. 41827; Phillips, M.A., Rathod, P.K., (2010) Infect. Disord. Drug Targets, 10, p. 226; (2005) Catalyst. Version 4.11 (Software Package), , http://www.accelrys.com, Accelry: San Diego, CA; Debnath, A.K., (2002) J. Med. Chem., 45, p. 41; Du, L.P., Tsai, K.C., Li, M.Y., You, Q.D., Xia, L., (2004) Bioorg. Med. Chem. Lett., 14, p. 4771; Li, M.Y., Tsai, K.C., Xia, L., (2005) Bioorg. Med. Chem. Lett., 15, p. 657; Gujjar, R., Marwaha, A., El Mazouni, F., White, J., White, K.L., Creason, S., Shackleford, D.M., Phillips, M.A., (2009) J. Med. Chem., 52, p. 1864; Phillips, M.A., Gujjar, R., Malmquist, N.A., White, J., El Mazouni, F., Baldwin, J., Rathod, P.K., (2008) J. Med. Chem., 51, p. 3649; Davies, M., Heikkila, T., McConkey, G.A., Fishwick, C.W., Parsons, M.R., Johnson, A.P., (2009) J. Med. Chem., 52, p. 2683; Boa, A.N., Canavan, S.P., Hirst, P.R., Ramsey, C., Stead, A.M., McConkey, G.A., (2005) Bioorg. Med. Chem., 13, p. 1945; Heikkila, T., Thirumalairajan, S., Davies, M., Parsons, M.R., McConkey, A.G., Fishwick, C.W., Johnson, A.P., (2006) Bioorg. Med. Chem. Lett., 16, p. 88; Brooks, B.R., Brooks, C.L., 3rd, Mackerell, A.D., Jr., Nilsson, L., Petrella, R.J., Roux, B., Won, Y., Karplus, M., (2009) J. Comput. Chem., 30, p. 1545; Smellie, S.L.T.A., Tobwin, P., (1995) J. Comput. Chem., 16, p. 171; Sprague, P.W., (1995) Perspect. Drug Discovery Des., 3, p. 1
PY - 2016
Y1 - 2016
N2 - Malaria, caused by infections of the human malaria parasites Plasmodium falciparum, is a global infectious parasitic disease. Each year, about three million people died from malaria and the majority of whom are pregnant women and young children. Recently, a number of research attempt to reduce malaria parasite resistance and the toxicity of anti-malarial drugs. Nowadays, Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) was validated as a potent drug target to inhibit malarial activity by blocking pyrimidine biosynthesis. In this study, we employed 3D-QSAR Pharmacophore Generation and Docking-Based Pharmacophore Development to build the pharmacophore by using the collected 67 effective inhibitors against PfDHODH. 3D-QSAR Pharmacophore model, Hypo1, shows the high correlation coefficient (0.935), the lowest RMS deviation (2.15), the predicting accuracy of successful rates to training set (89.4%) and test set compounds (72.4%), respectively, revealing favorable predictive ability and is a reliable for further study. Additionally, Docking-Based Pharmacophore model, DBP-All255, exhibits comparable predictive capability to that of Hypo1, while DBP-Top1 shows poor statistical significance. This study reveals pharmacophore features of Hypo1, built by 3D-QSAR Pharmacophore Generation, are well-complementary to the functional residues in the active site of PfDHODH and is of great reliable for database screening. © 2015 Elsevier Ltd. All rights reserved.
AB - Malaria, caused by infections of the human malaria parasites Plasmodium falciparum, is a global infectious parasitic disease. Each year, about three million people died from malaria and the majority of whom are pregnant women and young children. Recently, a number of research attempt to reduce malaria parasite resistance and the toxicity of anti-malarial drugs. Nowadays, Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) was validated as a potent drug target to inhibit malarial activity by blocking pyrimidine biosynthesis. In this study, we employed 3D-QSAR Pharmacophore Generation and Docking-Based Pharmacophore Development to build the pharmacophore by using the collected 67 effective inhibitors against PfDHODH. 3D-QSAR Pharmacophore model, Hypo1, shows the high correlation coefficient (0.935), the lowest RMS deviation (2.15), the predicting accuracy of successful rates to training set (89.4%) and test set compounds (72.4%), respectively, revealing favorable predictive ability and is a reliable for further study. Additionally, Docking-Based Pharmacophore model, DBP-All255, exhibits comparable predictive capability to that of Hypo1, while DBP-Top1 shows poor statistical significance. This study reveals pharmacophore features of Hypo1, built by 3D-QSAR Pharmacophore Generation, are well-complementary to the functional residues in the active site of PfDHODH and is of great reliable for database screening. © 2015 Elsevier Ltd. All rights reserved.
KW - 3D-QSAR Pharmacophore Generation
KW - Catalyst
KW - Docking-Based Pharmacophore Development
KW - PfDHODH inhibitor
KW - Pharmacophore
KW - dihydroorotate dehydrogenase
KW - dihydroorotate dehydrogenase inhibitor
KW - accuracy
KW - antimalarial activity
KW - Article
KW - correlation coefficient
KW - drug potency
KW - drug targeting
KW - IC50
KW - intermethod comparison
KW - malaria
KW - molecular docking
KW - nonhuman
KW - pharmacophore
KW - Plasmodium falciparum
KW - quantitative structure activity relation
U2 - 10.1016/j.bmcl.2015.12.043
DO - 10.1016/j.bmcl.2015.12.043
M3 - Article
SN - 0960-894X
VL - 26
SP - 265
EP - 271
JO - Bioorganic and Medicinal Chemistry Letters
JF - Bioorganic and Medicinal Chemistry Letters
IS - 2
ER -